Promoters hold 65.99 per cent stake: Low PE pharma penny stock below Rs 60; Company announces significant global expansion and strategic integration
The company has a market cap of Rs 287 crore and the stock is up by 6 per cent from its 52-week low of Rs 49.20 per share.
On Friday, shares of Balaxi Pharmaceuticals Ltd, surged 1.90 per cent to Rs 52 per share from its previous closing of Rs 41.03 per share. The stock’s 52-week high is Rs 151.45 per share and its 52-week low is Rs 49.20 per share.
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical company that focuses on the production, stocking, selling, and supply of both branded and generic medicines. With a substantial portfolio of 610 pharmaceutical product registrations, Balaxi offers a diverse range of products, including tablets, injectables, liquids, and capsules, sourced from WHO-GMP-certified contract manufacturers located in India, China and Portugal.
According to Quarterly Results, the net sales increased by 4 per cent to Rs 76.27 crore and net profit increased by 61 per cent to Rs 8.64 crore in Q4FY25 compared to Q3FY25. In its annual results (FY25), the net sales increased by 22 per cent to Rs 293 crore compared to FY24. The company reported a net profit of Rs 25 crore in FY25 compared to a net loss of Rs 2 crore in FY24, an increase of 1,350 per cent.
DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, do download the service details here.
In 2025 and the years that follow, Balaxi is poised for significant global expansion and strategic integration. Building on its successful entry into Honduras and El Salvador, the company plans to replicate its established business model by venturing into other Latin American countries, Southeast Asia, and CIS markets. A key initiative is the backwards integration of its supply chain, marked by the establishment of Balaxi's first pharma formulation manufacturing facility in Hyderabad, funded in part by a recently completed INR 47.57 crore preferential issue. The company will maintain a focus on an ideal mix of branded and generic medicines to maximise returns in key geographies, aiming for a strong global presence in potential frontier markets over the next five years, while also tapping into new channels for deeper penetration in its existing markets.
The shares of the company have a PE of 12x whereas the industry PE is 36x. The company has a market cap of Rs 287 crore and the stock is up by 6 per cent from its 52-week low of Rs 49.20 per share.
Disclaimer: The article is for informational purposes only and not investment advice.